358 related articles for article (PubMed ID: 3026540)
1. Prostaglandin endoperoxide analogues which are both thromboxane receptor antagonists and prostacyclin mimetics.
Armstrong RA; Jones RL; MacDermot J; Wilson NH
Br J Pharmacol; 1986 Mar; 87(3):543-51. PubMed ID: 3026540
[TBL] [Abstract][Full Text] [Related]
2. Functional and ligand binding studies suggest heterogeneity of platelet prostacyclin receptors.
Armstrong RA; Lawrence RA; Jones RL; Wilson NH; Collier A
Br J Pharmacol; 1989 Jul; 97(3):657-68. PubMed ID: 2474350
[TBL] [Abstract][Full Text] [Related]
3. Competitive antagonism at thromboxane receptors in human platelets.
Armstrong RA; Jones RL; Peesapati V; Will SG; Wilson NH
Br J Pharmacol; 1985 Mar; 84(3):595-607. PubMed ID: 2580580
[TBL] [Abstract][Full Text] [Related]
4. Prostaglandin E receptor subtypes in smooth muscle: agonist activities of stable prostacyclin analogues.
Dong YJ; Jones RL; Wilson NH
Br J Pharmacol; 1986 Jan; 87(1):97-107. PubMed ID: 2420404
[TBL] [Abstract][Full Text] [Related]
5. Octimibate, a potent non-prostanoid inhibitor of platelet aggregation, acts via the prostacyclin receptor.
Merritt JE; Hallam TJ; Brown AM; Boyfield I; Cooper DG; Hickey DM; Jaxa-Chamiec AA; Kaumann AJ; Keen M; Kelly E
Br J Pharmacol; 1991 Jan; 102(1):251-9. PubMed ID: 1710526
[TBL] [Abstract][Full Text] [Related]
6. Potentiation of aggregation and inhibition of adenylate cyclase in human platelets by prostaglandin E analogues.
Matthews JS; Jones RL
Br J Pharmacol; 1993 Feb; 108(2):363-9. PubMed ID: 8448586
[TBL] [Abstract][Full Text] [Related]
7. GR32191, a highly potent and specific thromboxane A2 receptor blocking drug on platelets and vascular and airways smooth muscle in vitro.
Lumley P; White BP; Humphrey PP
Br J Pharmacol; 1989 Jul; 97(3):783-94. PubMed ID: 2527074
[TBL] [Abstract][Full Text] [Related]
8. Prostaglandin endoperoxide/thromboxane A2 receptor desensitization. Cross-talk with adenylate cyclase in human platelets.
Murray R; Shipp E; FitzGerald GA
J Biol Chem; 1990 Dec; 265(35):21670-5. PubMed ID: 1701435
[TBL] [Abstract][Full Text] [Related]
9. Novel mechanism of heterologous desensitization of adenylate cyclase: prostaglandins bind with different affinities to both stimulatory and inhibitory receptors on platelets.
Ashby B
Mol Pharmacol; 1990 Jul; 38(1):46-53. PubMed ID: 1695318
[TBL] [Abstract][Full Text] [Related]
10. Heterogeneity of thromboxane A2 (TP-) receptors: evidence from antagonist but not agonist potency measurements.
Tymkewycz PM; Jones RL; Wilson NH; Marr CG
Br J Pharmacol; 1991 Mar; 102(3):607-14. PubMed ID: 1364826
[TBL] [Abstract][Full Text] [Related]
11. Effects of SQ 27,427, a thromboxane A2 receptor antagonist, in the human platelet and isolated smooth muscle.
Harris DN; Greenberg R; Phillips MB; Michel IM; Goldenberg HJ; Haslanger MF; Steinbacher TE
Eur J Pharmacol; 1984 Aug; 103(1-2):9-18. PubMed ID: 6090180
[TBL] [Abstract][Full Text] [Related]
12. Characterization of prostaglandin and thromboxane receptors expressed on a megakaryoblastic leukemia cell line, MEG-01s.
Watanabe T; Yatomi Y; Sunaga S; Miki I; Ishii A; Nakao A; Higashihara M; Seyama Y; Ogura M; Saito H
Blood; 1991 Nov; 78(9):2328-36. PubMed ID: 1718495
[TBL] [Abstract][Full Text] [Related]
13. Primate vascular responses to octimibate, a non-prostanoid agonist at the prostacyclin receptor.
Merritt JE; Brown AM; Bund S; Cooper DG; Egan JW; Hallam TJ; Heagerty AM; Hickey DM; Kaumann AJ; Keen M
Br J Pharmacol; 1991 Jan; 102(1):260-6. PubMed ID: 2043927
[TBL] [Abstract][Full Text] [Related]
14. The PGI2-analogue iloprost and the TXA2-receptor antagonist sulotroban synergistically inhibit TXA2-dependent platelet activation.
Stürzebecher S; Witt W
Prostaglandins; 1988 Dec; 36(6):751-60. PubMed ID: 2469101
[TBL] [Abstract][Full Text] [Related]
15. The use of stable prostaglandins to investigate prostacyclin (PGI2)-binding sites and PGI2-sensitive adenylate cyclase in human platelet membranes.
Lombroso M; Nicosia S; Paoletti R; Whittle BJ; Moncada S; Vane JR
Prostaglandins; 1984 Feb; 27(2):321-33. PubMed ID: 6326201
[TBL] [Abstract][Full Text] [Related]
16. Studies on antiplatelet effects of OP-41483, a prostaglandin I2 analog, in experimental animals. II. Mechanism of its antiplatelet effect.
Fujitani B; Wakitani K
Jpn J Pharmacol; 1990 May; 53(1):25-33. PubMed ID: 2161965
[TBL] [Abstract][Full Text] [Related]
17. Effects of heparin on prostacyclin binding and platelet adenylate cyclase activity stimulated by iloprost and forskolin.
Jaschonek K; Faul C; Daiss W; Weisenberger H
Prostaglandins Leukot Med; 1986 Oct; 24(2-3):199-206. PubMed ID: 2432618
[TBL] [Abstract][Full Text] [Related]
18. Binding to prostaglandin (PG) receptors and activation of adenyl cyclase by 20-isopropylidene-PGS in rabbit platelet membranes.
Ushiyama S; Handa S; Yamazaki M
Prostaglandins; 1988 Oct; 36(4):477-89. PubMed ID: 2853419
[TBL] [Abstract][Full Text] [Related]
19. SQ-27986 inhibition of platelet aggregation is mediated through activation of platelet prostaglandin D2 receptors.
Seiler S; Brassard CL; Federici ME
Prostaglandins; 1990 Aug; 40(2):119-30. PubMed ID: 2171039
[TBL] [Abstract][Full Text] [Related]
20. Characterization of the prostanoid receptor(s) on human blood monocytes at which prostaglandin E2 inhibits lipopolysaccharide-induced tumour necrosis factor-alpha generation.
Meja KK; Barnes PJ; Giembycz MA
Br J Pharmacol; 1997 Sep; 122(1):149-57. PubMed ID: 9298541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
